Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- lihegen
- Target Recruit Count
- 144
- Registration Number
- NCT03269162
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 167
- Registration Number
- NCT03267316
- Locations
- 🇩🇰
Rigshospitalet, Department of Oncology, Copenhagen, Denmark
🇦🇹Medizinische Universität Wien, Vienna, Austria
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT03256136
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT03242915
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon, Nashville, Tennessee, United States
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 145
- Registration Number
- NCT03233139
- Locations
- 🇯🇵
Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Osaka Medical College Hospital, Takatsuki, Osaka, Japan
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 719
- Registration Number
- NCT03215706
- Locations
- 🇺🇸
Local Institution - 0091, Wichita, Kansas, United States
🇺🇸Local Institution - 0004, Lexington, Kentucky, United States
🇦🇺Local Institution - 0086, Gosford, New South Wales, Australia
Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 74
- Registration Number
- NCT03193788
- Locations
- 🇰🇷
Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Dong-A University Medical Center, Pusan, Korea, Republic of
🇰🇷Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of
Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Registration Number
- NCT03190239
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03178552
- Locations
- 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 48
- Registration Number
- NCT03177291
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.